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The California Environmental Biomonitoring Program (also known as Biomonitoring California) has been
generating human biomonitoring data and releasing it via their website. The current Biomonitoring
California program is a collection of smaller studies, targeting speciﬁc populations (e.g., ﬁre ﬁghters,
breast cancer patients and controls, etc.). In this paper we compare the results from Biomonitoring
California with those from the US National Health and Nutrition Examination Survey (NHANES). We also
compare California's results with Biomonitoring Equivalents (BEs) for those compounds for which BEs
exist. In general, the results from California are consistent with the biomonitoring levels found across the
US via NHANES. A few notable exceptions are levels of ﬂame retardants amongst ﬁre ﬁghters in Cali-
fornia, which are higher than observed in NHANES and some persistent organic chemicals amongst a
study of breast cancer patients and controls in California which are higher than in the overall adult
population in NHANES. The higher levels amongst ﬁre ﬁghters may be a result of ﬁre ﬁghters being
exposed to higher levels of ﬂame retardants while ﬁghting ﬁres. The higher levels of the persistent or-
ganics amongst breast cancer patients is likely due to this population being older than the mean age in
NHANES. Comparisons to BEs indicate that biomonitoring levels in California are all consistently below
levels of concern as established by regulatory agencies.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The California Environmental Contaminant Biomonitoring Pro-
gram (also known as Biomonitoring California) is a multi-agency
program involving collaboration among three state agencies: the
Department of Toxic Substances Control (DTSC), the Ofﬁce of
Environmental Health Hazard Assessment (OEHHA), and the Cali-
fornia Department of Public Health. The program also has received
funding through the US Centers for Disease Control and Prevention
(CDC) to support capacity building and results evaluation and
communication efforts.
The program goals, as stated on the program website (www.
biomonitoring.ca.gov/), are to determine levels of selected envi-
ronmental chemicals in a representative sample of Californians,P.O. Box 427, Allenspark, CO
. Hays).
Inc. This is an open access article uestablish trends over time, and assess effectiveness of programs
designed to decrease exposures to speciﬁc chemicals. The program
includes a robust public communication and participation
component through thrice-yearly public meetings of the California
Biomonitoring Program's Scientiﬁc Guidance Panel (SGP) and a
responsive and extensive website (http://biomonitoring.ca.gov).
To date, the program has indicated that it has not been funded to
a level that allows a full execution of the goals and aims of the
program (see meeting minutes from the public meetings over the
past several years at http://biomonitoring.ca.gov). The limitations
imposed by the funding issuesmanifest in twoways. First, the list of
Designated Chemicals of interest compiled through an iterative
process with the SGP remains largely an aspirational list. While the
list includes more than 500 speciﬁc chemicals as well as several
chemical groups without speciﬁc enumeration of the chemicals
included, the program has reported results for approximately 140
chemicals across several independent studies (not all chemicals
monitored in all studies) (http://biomonitoring.ca.gov/chemicals/
chemicals-biomonitored-california). Second, until very recently,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is “representative” of the California population. Instead, the pro-
gram has strived to identify and interact with ongoing studies in
California that are examining various targeted populations and that
incorporate a biomonitoring component. Data are being generated
through independent studies for chemicals that are the subject of
the speciﬁc hypotheses in those studies, and although the analytes
may overlap to some degree with the Designated Chemicals list,
there is no current effort to comprehensivelymeasure the full list of
Designated Chemicals in studies in California.1
As of October 2014 there were no results available from a study
attempting statistically representative sampling of the California
population for age, gender, geography, or other representative ba-
sis. The California Biomonitoring Program has recently launched a
pilot and expanded study entitled Biomonitoring Exposures Study
(BEST) through a partnership with a managed care organization in
the Central Valley of California tomore closely approach the ideal of
a representative study (http://biomonitoring.ca.gov/projects/
biomonitoring-exposures-study-best-1pilot). However, as of the
date of data collection for this paper, results are not yet available
from either the pilot or expanded BEST studies. Instead, the Bio-
monitoring California program has organized and made available
summary statistics from a variety of targeted studies in California
that report biomonitoring data carried out by others, as noted
above.
Although the program is ongoing and results continue to be
reported out from ongoing studies, the Biomonitoring California
program now has posted a substantial body of results on their
website (http://biomonitoring.ca.gov/results/explore). The results
are reported as summary statistics, and raw data are not available.
Making use of this data, we provide a comparison of the reported
results from studies collected at the Biomonitoring California
website as of October 2014 to results from the US National Health
and Nutrition Examination Survey (NHANES) program. In addition,
in a manner analogous to previous activities to interpret US
NHANES and the Canadian Health Measures Survey (CHMS) bio-
monitoring data, the California biomonitoring results are inter-
preted in a public health risk context using Biomonitoring
Equivalents (BEs) and other similar risk-based biomonitoring
evaluation values (Aylward et al., 2013; St-Amand et al., 2014). Risk-
based interpretations are made using BEs, which are estimates of
concentrations of a chemical or its metabolites in a biological ma-
trix (e.g., blood, urine) corresponding to an exposure guidance
value such as an EPA reference dose (RfD) or tolerable daily intake
(TDI) (Angerer et al., 2011; Hays et al., 2007, 2008). These com-
parisons can be used to inform both evaluations of potential risks
from chemical exposures in the California population and the
design and focus of future studies in California.2. Methods
2.1. Biomonitoring California program data
Summary statistics for all projects with reported results were
downloaded from the Biomonitoring California website on October
27, 2014. The results included those from seven independent bio-
monitoring studies (Table 1) and encompass analytes from1 Biomonitoring California has recently received an additional grant from the
Centers for Disease Control (CDC) and Prevention that will support expansion of
their goals (http://biomonitoring.ca.gov/biomonitoring-california-awarded-5m-
centers-disease-control). Biomonitoring California states they will “use the fund-
ing during the ﬁrst year to establish statewide surveillance for environmental
contaminants in maternal serum samples”.numerous chemical classes including legacy organochlorine pesti-
cides (OCPs), polybrominated diphenyl ethers (PBDEs), current use
pesticides, metals, polychlorinated biphenyls (PCBs), polycyclic ar-
omatic hydrocarbons (PAHs), polyﬂuoroalkyl compounds (PFAS),
environmental phenols, phthalate esters, and a benzophenone
derivative in widespread use in sunscreen preparations. Data from
each study remain in the custody of the study teams; summaries of
results are reported to the Biomonitoring CA program and made
available on the Biomonitoring CAwebsite. Thus, raw data from the
independent studies are not available for analysis. Geometric
means for the datasets were reported only when detection rates
exceeded 65%.
2.2. NHANES program data
Summary statistics for analytes from the US NHANES bio-
monitoring program were downloaded from the CDC webpage.
Speciﬁcally, updated tables from the Fourth National Exposure
Report (CDC, 2014) were used to extract geometric mean and
conﬁdence interval estimates for population groups corresponding
to those examined in the California studies (see Table 1). The best
available match for demographic (e.g., females or adults) and year
of sampling was selected. For selected persistent organic pollutants
(POPs), statistics reported for speciﬁc age groups were obtained
from Patterson et al. (2009).
Comparisons between the CA study results and NHANES
focused on comparison of geometric means and their associated
conﬁdence intervals. Formal statistical comparisons were not
attempted because of certain limitations: the raw data from the CA
studies were not available; the speciﬁc age and in some cases
gender compositions of the CA studies were not available; and no
indication of population representativeness with respect to vari-
ables considered in the NHANES sampling protocols were available.
Comparisons at higher population percentiles (e.g., the 95th
percentile) were not made because in general the studies presented
on the CA Biomonitoring program website were relatively small
(<200 individuals), and although 90th or 95th percentile estimates
were reported, no conﬁdence intervals on those values were
calculated or reported. As a result, a valid comparison to NHANES
upper percentiles was not possible. In addition, for non-persistent
chemicals such as the phthalates, environmental phenols, para-
bens, and some of the pesticides. Both lower and upper bounds of
distributions of spot sample concentrations are likely to be rela-
tively unstable due to large intra-individual variation in biomarker
concentrations for such compounds (Aylward et al., 2012). Thus,
comparisons at central tendencies provide a more stable assess-
ment of relative population exposure levels.
2.3. Risk assessment-based interpretation
Information on pharmacokinetics has previously been used to
estimate biomarker concentrations that are consistent with exist-
ing exposure guidance values such as EPA RfDs, or Health Canada
TDIs, or similar values (reviewed in Aylward et al., 2013). These
biomonitoring based assessment values have variously been called
Biomonitoring Equivalents (BEs; Hays et al., 2007, 2008) or Human
Biomonitoring values (HBM values; Angerer et al., 2011). These
values can be used as screening tools to evaluate whether
biomarker concentrations are signaling exposures that are well
below, near, or at or above levels consistent with population level
risk assessment-based exposure guidance values.
The BE values and other similar guidance values are generally
estimates of steady-state or average biomarker concentrations
corresponding to an intake exposure guidance value that has been
developed for chronic exposures. For example, a BE derived from an
Table 1
Studies with summary statistics included in the Biomonitoring California results as of 10/31/14. The population subset from NHANES used as a comparison population in the
current review is described in the ﬁnal column of the table.
Study Population description Time period of
sampling
Chemicals analyzed NHANES comparison population and
time period
Maternal and Infant
Environmental
Exposure Project
(MIEEP)
92 pregnant women from San
Francisco. Sampling occurred during
the third trimester of pregnancy.
2010e2011 Environmental phenols, metals,
phthalates, PAHs, and
pyrethroids in urine; OCPs,
PBDES, PCBs, PFAAs in serum
Females, 2009e2010 except for PAHs
(2007e2008); and OCPs, PBDEs, and
PCBs (2003e2004).
Fireﬁghter Occupational
Exposures (FOX) Project
101 Fireﬁghters from southern
California
2010e2011 Environmental phenols incl.
benzophenone derivatives,
herbicides, metals, phthalates,
PAHs, and pyrethroids in urine;
OCPs, PBDES, PCBs in serum
Adults, 2010e2011 except for PAHs
(2007e2008) and OCPs, PBDEs, and
PCBs (2003e2004).
California Childhood
Leukemia Study (CCLS)
48 women with children ages 0 to 14
between 1999 and 2005 (Whitehead
et al., 2015); mothers of either cases of
leukemia or controls.
2006e2007 OCPs, PCBs, and PBDEs in serum Females, 2003e2004
California Teachers
Study (CTS)
2500 current or former teachers or
school administrators; cases with
breast cancer or controls. Currently,
results are reported for a subset of these
samples (n ¼ 168) because sample
analysis is not complete.
2011 OCPs, PCBs, PBDEs, and PFAAs
in serum
Females, 2003e2004 (BDEs, OCPs,
PCBs)
Females, 2009e2010
(PFAAs)
Center for the Health
Assessment of Mothers
and Children of Salinas
(CHAMACOS)
49 children age 5 from agricultural
communities in the Salinas valley.
2005e2006 Phthalate metabolites in urine Children ages 6 to 11, 2005e2006
Markers of Autism Risk in
BabieseLearning Early
Signs (MARBLES)
15 pregnant women who have a child
previously diagnosed with autism
spectrum disorder.
2007e2008 Phthalate metabolites in urine Females, 2007e2008
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manner analogous to the way the RfD is used to interpret human
oral exposures. For example, a health risk based interpretation of
oral exposures involves comparing the estimated average daily
lifetime intake in mg/kg-day to the oral RfD, where the oral RfD is
deﬁned as “an estimate [of oral exposure in mg/kg-day] (with un-
certainty spanning perhaps an order of magnitude) of a daily oral
exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious effects
during a lifetime” (EPA glossary http://www.epa.gov/risk_
assessment/glossary.htm#r). Using knowledge of toxicokinetics, a
BE can be developed from a RfD, resulting in a health risk-based
guidance value in units of concentration (in urine or blood) that
corresponds to the applied dose RfD value. Thus, a BERfD can be
viewed as to the average daily lifetime concentration value (in
blood or urine) “that is likely to be without appreciable risk of
deleterious effects in a lifetime,” in the population, including sen-
sitive subgroups. Human biomonitoring data can be interpreted in
a population human health risk context by comparing the
measured levels (in blood or urine) to the corresponding BE.
Measured biomarker concentrations far below the corresponding
BE value suggest that exposures are generally well below levels
deemed tolerable in a risk assessment context. Measured
biomarker concentrations near or above the BE value indicate ex-
posures may be approaching or exceeding risk assessment-based
guidance values.
This framework must be considered in the interpretation of
distributions of biomarker concentrations in spot samples collected
randomly from populations. For highly persistent compounds (e.g.,
legacy organochlorine compounds and some metals), measure-
ments in spot samples are likely to be representative of longer term
average concentrations. However, for chemicals that are rapidly
absorbed, metabolized, and eliminated in the body, a spot sample
concentration may vary widely over the course of a day or from day
to day in an individual, depending on the timing of samplecollection compared to last exposure to the substance (Aylward
et al., 2012; Preau et al., 2010; Ye et al., 2011). For this reason, ex-
tremes of the distributions of concentrations of spot samples for
such compounds are unlikely to represent longer-term average
concentrations for any individual. For such transient compounds,
comparisons to BE values should be conducted for central tendency
summary statistics (geometric or arithmetic means) rather than for
population extreme values (Aylward et al., 2012, 2013; St-Amand
et al., 2014).
3. Results
3.1. Comparisons by chemical group
The main comparisons of the California and NHANES datasets
are presented as graphs comparing the geometric means and
conﬁdence intervals for each chemical group. Only those chemicals
with detection rates in both surveys high enough to reliably
calculate geometric means are presented and compared. In each
graph, estimates of geometric means from each California study
reporting data on the Biomonitoring California website for a given
analyte are presented paired to the corresponding NHANES sub-
population geometric mean (see Table 1 for description of the
speciﬁc NHANES subpopulation used for comparison to each of the
studies).
3.1.1. Environmental phenols
Data for several environmental phenols and methyl paraben
were available from the FOX and MIEEP studies (see Table 1 for
study descriptions). Comparison of geometric means between
these studies and the NHANES program showed that the spread of
conﬁdence intervals on the geometric means in the California
studies and the NHANES datasets generally overlapped. The simi-
larity of levels between the California studies and the NHANES
Fig. 1. Log scale plot of comparative geometric means and 95% CIs for environmental
phenols and related chemicals in urine (mg/L) in California studies and NHANES
comparison subpopulations.
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similar between the California sub-populations and the general US
population (see Fig. 1).3.1.2. Phthalates
Fig. 2 presents the comparative GM values from the various
California studies and corresponding NHANES subgroups for
phthalate metabolites. In general, GM phthalate metabolite
concentrations in urine were similar to those in the
comparison NHANES populations. However, for mono(2-ethyl-5-
carboxypentyl) phthalate (MECPP), a metabolite of di(2-
ethylhexyl) phthalate (DEHP), levels were slightly lower in the
FOX study than in the corresponding NHANES comparison group.
Levels for mono(3-carboxypropyl) phthalate (MCPP), a metabolite
of di-n-octylphthalate, were lower in the MIEEP cohort than in the
corresponding NHANES group. Conversely, mono-n-butyl phtha-
late (MnBP) concentrations were higher in the CHAMACOS cohort,
but not in other California studies. The GM for the CHAMACOS
cohort (children aged 5) was approximately 50% higher than the
NHANES GM for children ages 6 to 11 (the closest corresponding
group age, 30.5 vs. 19.5 ng/ml in urine). Available information toFig. 2. Phthalate metabodetermine the underlying differences in children's exposures be-
tween the CHAMACOS population and the NHANES population is
lacking, although lifestyle factors associated with socio-economic
status and ethnicity may be factors to consider (Tyrrell et al.,
2013; Zota et al., 2014).
Differences in the other direction were also observed. The GM
for MECPP, a major metabolite of DEHP, was approximately 40%
lower in the FOX cohort than in the corresponding NHANES data for
adults (12.3 vs.19.4 ng/ml) and the GM forMCPP, a metabolite of di-
n-octylpthalate, was threefold lower than the corresponding
NHANES GM (0.87 vs. 2.72 ng/ml).
3.1.3. PAHs
Fig. 3 illustrates the comparative urinary PAH concentrations
among the California studies and corresponding NHANES groups.
In general, the relative pattern of PAH levels are similar between
those in the California studies and the NHANES program. There are
some differences in GMs for speciﬁc PAH metabolites.
1-Hydroxynapthalene (1-NAP) is lower by a factor of 2 or more
in both the FOX and MIEEP studies than in the NHANES program.
Similarly, 3-hydroxyﬂuorene (3-FLUO) is also lower in the CA
studies. 1-Hydroxyphenanthrene (1-PHEN), 1-hydroxypyrene (1-
PYR), 2-hydroxynapthalene (2-NAP), 2-hydroxyphenanthrene (2-
PHEN), and 9-hydroxyﬂuorene (9-FLUO) are higher in one or the
other of the two studies examining these markers from California
than in NHANES, with differences varying from a factor of about
50e100%. Some caution must be attached to these comparisons
because the most recent NHANES cycle with PAH data was the
2007e2008 cycle, while the California data generally come from
2010 to 2011. And while there do not seem to be strong trends in
the PAH data in NHANES prior to the 2007e2008 cycle, the GMs in
NHANES do seem to vary notably from cycle to cycle for several of
these analytes. This likely reﬂects signiﬁcant within- and between-
individual variability in the urinary concentrations of these analy-
tes, in part due to their short elimination half-lives (Li et al., 2010).
Possible differences associated with prevalence of smoking cannot
be evaluated since smoking status was not provided as part of the
California studies.
3.1.4. Organochlorine pesticides
Measured serum lipid-adjusted concentrations of legacy
organochlorine pesticides (Fig. 4) are generally lower in Californialites in urine, mg/L.
Fig. 3. PAH metabolite concentrations in urine, mg/L.
Fig. 4. Serum lipid-adjusted concentrations of legacy organochlorine pesticides, ng/g lipid.
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because the comparison data available is from 2003 to 2004, while
the California data has generally been measured more recently
(2010e2011, except for the CCLS study, in which samples were
taken 2006 to 2007). The general population in the US has generally
demonstrated downward trends in the concentrations of these
chemicals with time, so samples taken more recently generally are
lower than earlier time points. However, levels in the CTS study are
very similar to those reported in the NHANES 2003e2004 dataset
for adults of all ages, despite the fact that the samples were taken 7
years later. This may reﬂect the older age of the CTS study popu-
lation (discussed further below).
3.1.5. PBDEs
The pattern of comparative PBDE GM concentrations was quite
variable among the California studies and in comparison with the
NHANES data (Fig. 5). In general, PBDE concentrations were higher
in the FOX and CCLS studies than in the CTS and MIEEP studies.
Consistent with that, the GM concentrations of several analytes in
the FOX and CCLS studies were higher than the NHANES GMs, while
the GM values from the CTS and MIEEP studies were generally
lower than or similar to the NHANES GMs. Sampling occurred a few
years earlier for the CCLS (2006e2007) compared to the CTS,
MIEEP, and FOX studies, in which sampling occurred in 2010e2011.The most recent NHANES data available for comparison is based on
samples collected in 2003e2004. These differences in collection
time period might have affected the comparability of levels. In
addition, because the FOX cohort is an occupational cohort of
ﬁreﬁghters, it is possible that the higher levels in this cohort reﬂect
occupational exposures rather than general environmental expo-
sure levels. However, this does not address the differences between
the CCLS and MIEEP studies, both of which examine levels in
samples fromwomen of childbearing ages. The CCLS samples were
collected somewhat earlier than the MIEEP samples (2006e2007
vs. 2010e2011) but it is not clear that the differences reﬂect any
generalized temporal trend. The NHANES data are not helpful in
resolving this issue, as only one time point (2003e2004) is avail-
able from NHANES.3.1.6. PFAAs
PFAAs were measured in the CTS and MIEEP studies (Fig. 6). In
general, levels in these two studies were similar to or lower than
those reported in the NHANES program. In the MIEEP program,
measured levels were lower for 2-(N-Methyl-perﬂuorooctane sul-
fonamido) acetic acid (Me-PFOSA-AcOH) and perﬂuorooctane sul-
fonate (PFOS). In the CTS, perﬂuorohexane sulfonate (PFHxS)
concentrations were slightly higher than in NHANES females.
Fig. 5. Serum lipid-adjusted PBDE concentrations, ng/g lipid.
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PCB concentrations were measured in four of the California
studies (FOX, CTS, CCLS, and MIEEP), and levels compared to the
reference NHANES datasets are presented in Fig. 7. Detections were
frequent enough to characterize GM concentrations in most of the
studies for a range of PCB congeners. In general, concentrations
measured in these studies were lower than the NHANES data,
which date from 2003 to 2004, with the exception of the data from
the CTS. As with the OCPs, PCBs have generally exhibited a
decreasing trend with time in the US, so levels for most of these
congeners would be expected to be at least somewhat lower in the
CA studies, which collected blood up to 7 years after the most
recent NHANES cycle with data. As with the OCPs, the CTS, which is
comprised of an older study population, has higher GMs than the
other CA studies. This may reﬂect a difference in age distribution
between the CTS study population, which is comprised of breast
cancer cases and controls, compared to several other study pop-
ulations, which are comprised of pregnant women and/or mothers
of younger children. However, details on the age distribution in the
California studies are not available in order to conﬁrm this.
3.1.8. Metals
Selected metals were measured in urine and blood in the MIEEPFig. 6. PFAAs in sproject, and in urine only in the FOX project (Fig. 8). Urinary arsenic
levels in the FOX and MIEEP projects (GMs of 10.8 and 7.71 mg/L,
respectively) were generally similar to NHANES (GMs of 10.2 mg/L in
adults and 8.55 mg/L in females), while urinary cadmium levels in
the FOX and MIEEP projects (GMs of 0.145 and 0.185 mg/g creati-
nine, respectively) were lower than the comparable NHANES data
(GMs of 0.242 mg/g creatinine in adults and 0.233 mg/g creatinine in
females). For metals in blood, GM levels of cadmium, lead, and
mercury were all lower than the corresponding levels in the
NHANES program (Fig. 8).
3.1.9. Current use pesticides
Urinary markers for a number of current use pesticides were
measured in several of the California studies. In general, few
comparisons could be made due to low detection rates in NHANES
or the CA studies. Detection rates were high enough to allow
calculation of GMs for TCPy, a metabolite and environmental
degradate of chlorpyrifos, in the FOX and MIEEP studies (GMs of 1.8
and 0.5 ng/ml, respectively). These GMswere generally similar to or
lower than levels reported in the 2001e2002 NHANES program
(1.5 ng/ml). Levels of 3-phenoxybenzoic acid (3-PBA), a non-
speciﬁc metabolite of pyrethroid pesticides, in the FOX study (GM
of 0.5 ng/ml) were generally similar to the NHANES program
(0.4 ng/ml).erum, ng/ml.
Fig. 8. Metals measured in blood in the MIEEP program, ug/L (cadmium and mercury)
or ug/dL (lead).
Fig. 7. Serum PCB concentrations, ng/g lipid.
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California biomonitoring results in a public health risk context
Previously, data from the NHANES and CHMS programs were
compared to available BE values and other available assessment
values (Aylward et al., 2013; St-Amand et al., 2014) to provide a
cross-chemical evaluation of the relative levels of biomarker con-
centrations compared to risk assessment levels. Biomonitoring
Equivalents (BEs) or other similar assessment values are available
for a number of the analytes included in the California studies
(Table 2), enabling us to conduct a similar cross-chemical risk-
based evaluation. For these analytes, GM biomarker concentration
data from the California studies are generally well below the cor-
responding BE or other risk-based biomonitoring guidance values.
Even at upper percentile values from these studies (90th or 95th,
depending upon the study) levels are consistently below the cor-
responding BE values in each case. For BPA, triclosan, speciﬁc
phthalate metabolites, and PBDE 99, the GM levels reported in the
California biomonitoring studies are 100's-to 1000's-fold lower
than the BE values. For 2,4-dichlorophenoxyacteic acid, GM levels
were 10,000-fold below the BERfD. For hexachlorobenzene, cad-
mium and mercury, the GM levels are on the order of 4- to 50-fold
Table 2
Comparison of biomonitoring results for analytes from the California biomonitoring studies to corresponding BE values or other biomonitoring-based assessment values.
Exposure guidance Values Corresponding BE or other biomarker
guidance value
California study resultsa
Analyte (Parent compound,
if different)
Type, source, yr Value (mg/kg-d) Value Biomarker units
and matrix
Ref.b California
study
GM (95% CI) P90 P95 Ratio,
GM/BE
Bisphenol A RfD, EPA, 1993 0.05 2000 ug/L urine 1 FOX 1.58 (1.25, 1.99) 11.9 0.0008
MIEEP 1.25 (0.984, 1.58) 4.85 0.0006
Triclosan RfD, EPA, 2008 0.3 6400 ug/L urine 2 FOX 20.2 (13.5, 30.2) 563 0.0032
MIEEP 17.2 (10.5, 28.2) 445 0.0027
Mono-ethylphthalate
(Diethyl phthalate)
RfD, EPA, 1993 0.8 18,000 ug/L urine 3 FOX 52.9 (38.1, 73.4) 740 0.0029
CHAMACOS 85 (63.1, 115) 403 0.0047
MARBLES 65.1 (26, 163) 0.0036
MARBLES 62.4 (32.2, 121) 0.0035
MIEEP 95.5 (69.3, 132) 679 0.0053
Mono-n-butyl phthalate
(Dibutyl phthalate)
RfD, EPA, 1990 0.1 2700 ug/L urine 3 FOX 10.6 (8.83, 12.8) 40.6 0.0039
CHAMACOS 46.9 (37, 59.4) 115 0.0174
MARBLES 21.9 (14.4, 33.5) 0.0081
MARBLES 21.1 (10.8, 41.2) 0.0078
MIEEP 16.3 (13, 20.5) 60.8 0.0060
Mono-benzylphthalate
(Benzylbutyl phthalate)
RfD, EPA 1993 0.2 3800 ug/L urine 3 FOX 8.18 (6.56, 10.2) 41.3 0.0022
MIEEP 7.73 (5.84, 10.2) 53.4 0.0020
Hexachlorobenzene MRL, ATSDR, 2002 5E-05 47 ng/g serum lipid 4 FOX 11.8 (11.3, 12.4) 17.6 0.2511
CCLS 7.7 (7.2, 8.1) 10 0.1638
CTS 13.1 (12.6, 13.7) 21.6 0.2787
MIEEP 8.26 (7.58, 8.99) 12.5 0.1757
PBDE 99 RfD, EPA, 2008 520 ng/g serum lipid 5 FOX 6.19 (5.35, 7.17) 22.6 0.0119
CCLS 11 (8.5, 14) 25 0.0212
CTS NC 15.6 NC
MIEEP NC 9.92 NC
Cadmium RfD, EPA, 1994 0.0005 in water;
0.001 in food
2 ug/g cr 6 FOX 0.145 (0.132, 0.16) 0.277 0.0725
MIEEP 0.185 (0.16, 0.213) 0.364 0.0925
Mercury 5.8 ug/L blood 7 MIEEP 0.45 (0.37, 0.54) 1.1 0.0776
2,4-Dichlorophenoxyacetic
acid
RfD, EPA, 2011 0.21 mg/kg-d 8600 ug/L urine 8 FOX 0.27 (0.21, 0.34) 1.46 0.0001
NCenot calculated due to detection rate < 65%.
a Biomarker matrix and units the same as for the BE values in the previous set of columns.
b References for biomonitoring assessment values: 1: Krishnan et al., 2010a; 2: Krishnan et al., 2010b; 3: Aylward et al., 2009; 4: Aylward et al., 2010; 5: Krishnan et al. 2011;
6: Hays et al., 2008; 7: NAS, (2000); 8: Aylward and Hays (2008), modiﬁed to reﬂect updated RfD of 0.21 mg/kg-d (US EPA, 2013).
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As discussed above, comparison of the upper percentiles to BE
values may be appropriate for persistent compounds such as PFCs,
PFAA, PBDEs, and legacy organochlorine compounds such as HCB.
However, for highly transient compounds this comparison is likely
to overestimate the relative level of longer-term exposure
compared to the BE values for individuals in the population.
Overall, the pattern of results suggest that exposures to the
chemicals for which comparison values are available are occurring
at levels well below the limits identiﬁed as being tolerable expo-
sure levels.4. Discussion
For many biomonitored chemicals, levels observed in the CA
studies are generally similar to those observed in comparable
subpopulations in the NHANES program. This should provide some
conﬁdence in the representativeness of the NHANES program re-
sults. Some differences for individual chemicals and for some
chemical groups between the CA study results and the corre-
sponding NHANES data were observed. Levels of some PAH com-
pounds in urine varied from those observed in NHANES. These
compounds can be markers of exposure to combustion-related
substances, including smoking, air pollution and combustion-
related byproducts in food preparation (Li et al., 2010). Bio-
markers for these compounds are highly transient and sampled
levels can vary widely within- and between-individuals over short
time periods (Li et al., 2010). Inspection of the available NHANES
data over time also show that GM levels in the NHANES surveyshave ﬂuctuated substantially from one cycle to the next for some
PAHs. This suggests that differences in biomarker concentrations
for these compounds between studies or over time must be inter-
preted cautiously with respect to understanding longer-term
average exposure levels.
The concentrations of lipophilic persistent compounds were
frequently higher in the CTS study than in the other studies in CA,
and higher than general reference values from the NHANES studies
for adults. As previously noted, the CTS study likely includes a
distribution of individuals that is older than in some of the studies
of women of reproductive age, since the CTS study population
consists of cases of women with breast cancer and matched con-
trols (In the US, the median age of women at diagnosis of breast
cancer is 61, and is most frequently diagnosed in women ages
55e64 [http://seer.cancer.gov/statfacts/html/breast.html]). Con-
centrations of lipophilic persistent compounds such as PCBs, DDT
and metabolites, and HCB are generally higher in older individuals
due to historically higher exposure levels (Patterson et al., 2009).
Fig. 9 shows the CTS geometric mean results for selected PCBs, DDE,
and HCB in comparison to age-group speciﬁc GMs for ages 40 to 59
and 60þ from NHANES as reported by Patterson et al. (2009). The
levels measured in the CTS study are similar to those reported in
the NHANES dataset for adults in these age groups. Thus, this dif-
ference in levels observed in the main comparison of CTS results to
those for all adults in NHANES are likely due to a shift in the age
distribution in the CTS to older age on average than for all adults in
NHANES.
Some PBDE compounds exhibited higher concentrations in the
FOX and certain other CA studies than in the comparison NHANES
Fig. 9. Comparison of CTS GMs for selected POPs (ng/g serum lipid) to GMs measured in adults age 40 to 59 and 60þ in NHANES.
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FOX study, it is possible that as ﬁreﬁghters, the participants may be
exposed to ﬂame retardant materials released in ﬁre situations at a
rate higher than the general population.
One of the greatest challenges faced in reporting human bio-
monitoring studies to stakeholders is interpretation of the results.
In 2006, a National Academy of Sciences report on human bio-
monitoring (NRC, 2006) noted that “the ability to detect has out-
paced the ability to interpret health risk,” and recommended
approaches to enhance risk-based interpretations (e.g., Chapter 5,
NRC 2006). Subsequently, BEs were developed (Hays et al., 2007;
Angerer et al., 2011) and used to interpret biomonitoring data-
sets, including the US NHANES data (Aylward et al., 2012) and data
from the Canadian Health Measures Survey (St-Amand et al.,
2014).
We have now extended such analyses to the California Bio-
monitoring Program datasets. Health risk-based biomonitoring
guidance values (e.g., BEs) were available for only a subset of the
chemicals included in the studies collected through the California
Biomonitoring Program. Comparison of the levels observed in these
California studies to BEs (or similar biomonitoring interpretation
guidance values) shows that in general, levels in the California
studies are below or well below the corresponding assessment
values. Even in cases where GM levels are higher in the California
studies than in the NHANES datasets (e.g., for MnBP), the levels
observed remain well below BE values or other risk assessment-
based biomonitoring interpretation standards, i.e. there is an
adequate margin of safety.
For individual substances, such a hazard index interpretation
approach is consistent with procedures used for evaluating po-
tential human health risks from exposures (applied doses or in-
takes) in California's Air Toxics Hot Spots Program (http://oehha.ca.
gov/air/hot_spots/2014/SRP2014/
SRPReviewSept2014GuidanceManual.pdf), California's drinking
water programs (http://www.waterboards.ca.gov/drinking_water/
certlic/drinkingwater/MCLsandPHGs.shtml) and California's haz-
ardous waste sites and permitted facilities program (http://www.
dtsc.ca.gov/AssessingRisk/upload/HHRA-Note-3-2.pdf). Dourson
et al. (2013) recommended that, to enhance interpretation and
communication of biomonitoring results in the context of potential
human health risks, biomonitoring investigations, such as those
within the California Program, should utilize interpretation tools
such as BEs, noting that interpretations based only on consideration
of presence “should be actively discouraged.”Where differences in GM levels are observed between the CA
studies and the NHANES datasets, these differences are generally
within a half-order of magnitude (factor of 3) or less. To the
extent that the observed differences represent long term differ-
ences in exposure levels, this magnitude of difference may be of
concern if population exposure levels are near or above tolerable
exposure levels based on toxicological data and risk assessment
practices. However, this magnitude of difference tends to fall
within the range of uncertainty in the development of such
exposure guidance values, which typically include order-of-
magnitude uncertainty factors for inter- and intra-individual
variations.
The pattern of results observed in the California studies reported
to date in comparison to the NHANES program suggests that in
general exposures in California for many compounds are generally
similar to those found across the US, and where levels differ
somewhat, the magnitude of difference is generally less than a
factor of three. There are several implications of this observation.
First, these results suggest that the general patterns of exposure for
chemicals currently being biomonitored in the US may not differ to
a great degree in different regions of the country. This suggests that,
for purposes of providing a general indication of population
exposure levels, smaller studies than NHANES may provide useful
information. This conclusion depends of course on the degree of
precision in exposure level required and the purpose of the speciﬁc
exposure evaluation.
Second, these results suggest that studies in California designed
to provide a population-representative sampling program (e.g., the
developing BEST program) should consider including speciﬁc tar-
geted objectives in order to supplement the overall goal of gener-
ating California population-representative data, since in many
cases the data are likely to be very similar to those from the
NHANES program. These objectives could include investigation of
the apparent differences observed for selected analytes in the
studies to date compared to the NHANES program, examination of
supplementary classes of chemicals compared to thosemeasured in
the NHANES program, or measurement in specimens from popu-
lation groups not widely represented in the NHANES program, e.g.,
children under 6.
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